PharmiWeb.com - Global Pharma News & Resources
03-Feb-2020

Applied Photophysics board appoints Tim Flanagan as CEO

Surrey, UK – 3rd February 2020 – Life Science Newswire Applied Photophysics Limited, a world leader in biophysical characterization of biomolecules, has today announced that its Board of Directors has appointed Tim Flanagan as Chief Executive Officer and member of the Board of Directors effective immediately. Additionally, Marc Neglia has been appointed President of Applied Photophysics Inc. to lead operations in the Americas and will also be an executive member of the Board of Directors for Applied Photophysics Limited. Tim succeeds Paul Walker who has been acting as Interim CEO for the past year and who will continue to support Tim in a transition period before he resumes his previous role as a non-executive member of the Applied Photophysics board.


"Tim brings a wealth of relevant experience having been a commercial executive for many organisations which Applied Photophysics respect and admire as peers in the industry. Over the past few months Tim has advised our commercial approach in one of our strategically most important areas. In this period, he has demonstrated his ability to assess, analyse and drive both people and organisations in a commercially successful direction. Skills which we value highly. I look forward to continuing working closely with Tim", said David Berglund, Chairman Applied Photophysics.

Tim has over 25-years of leadership experience in the life sciences tools markets and has previously held senior roles in Bioquell, GE Life Sciences, MicroCal, Bio-Rad, and Beckman Coulter.

"I am honoured to be joining the company in such an exciting phase," says Tim "the company is positioned with fantastic technology and a reputation that is second to none within its core markets. Fundamental research is as important as it ever was and with the increasing influence of biopharmaceuticals on health management, systems for the analysis of safe and effective therapeutics are in strong demand. Applied Photophysics is at the forefront of in-depth bioanalytical testing. I would also like to thank Paul and the rest of the Applied Photophysics board for the past 12 months, setting the company up for future growth."

David adds "I would also like to congratulate Marc on his promotion to President of Applied Photophysics Inc. Over his 18 months with us, Marc has demonstrated a strong ability to understand and meet customer needs even in difficult environments. In this short period, Marc has tuned a strong group of individuals into a highly performing team. With the increased control that Applied Photophysics Inc. will give Marc, I am convinced that he will continue to excel in delivering strong results".

Marc has more than 25 years of senior leadership experience, which includes a decade of leading high performing sales teams that have delivered exceptional growth in the biotech and scientific sectors. Most recently, as the North American Sales Director at Applied Photophysics, Marc has helped to re-establish the company as a key player in the protein characterization market. He holds a BS Degree in Electronics Engineering from Thomas Edison State University and an MBA Degree from Drexel University.

"I have been fortunate to lead an exceptional team of individuals here in the US for the past year and a half, and I’m both excited and honored to have the opportunity to continue and build on the success that we have been able to achieve recently. As a market leader in the biopharmaceutical and academic communities, Applied Photophysics Inc. is very well positioned to enhance our market presence in the Americas" says Marc.


About Applied Photophysics

Applied Photophysics, headquartered in Leatherhead, Surrey, UK, is a leading provider of solutions for biophysical characterization of biomolecules. Chirascan™ systems use the phenomenon of circular dichroism (CD) to characterize changes in the higher order structure of proteins. These systems are used in cutting-edge research and to support the development of innovator drugs and biosimilars in the biopharmaceutical industry. The Company’s SX-range of stopped-flow spectrometers is acknowledged globally as the gold standard for kinetic studies of fast biochemical reactions.

Please visit https://www.photophysics.com/ for more information.

Applied Photophysics board appoints Tim Flanagan as CEO

Editor Details

Last Updated: 06-Feb-2020